LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Lifesciences | Diagnostic & Biotechnology

LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Market by Therapeutics, Diagnostics, and Country Outlook | Forecast 2022-2028

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

As per Triton Market Research, the Latin America Alzheimer’s disease therapeutics and diagnostics market is likely to grow with a CAGR of 6.19% over the estimated period between 2022 and 2028.



Report scope can be customized per your requirements. Request For Customization 

The countries analyzed in this region include:

•         Mexico

•         Brazil

•         Rest of Latin America

Various countries in the region are initiating national-level healthcare plans for dementia patients. However, they encounter substantial challenges when it comes to providing an accurate dementia diagnosis and effective care. Overall though, the market for Alzheimer’s disease therapeutics and diagnostics is expected to observe steady growth over the considered period.

Data from the World Population Ageing 2019 report suggests that there were nearly 19.526 million people in Brazil aged 65 years or older, as of 2019. By 2030, it is expected that nearly 30.413 million will fall in this age group. The older population is predicted to increase over the coming years, and thus, the demand for AD therapeutics and diagnostics is anticipated to expand. This is because they are more prone to neurological conditions like Alzheimer’s disease and dementia.

In Rest of Latin America, the rising number of awareness campaigns by government as well as non-government organizations are anticipated to increase the demand for early disease detection and treatment. This is expected to drive the market’s expansion. For instance, in Chile, the Corporacion Alzheimer Chile is working towards educating the public about Alzheimer’s disease. These factors are expected to foster the studied market’s growth in the coming years.

At the prodromal disease stage, there are evident signs of brain dysfunction. Aducanumab and other candidate A vaccines will be recommended for the treatment of prodromal and mild AD if they receive approval. According to a 2020 Practical Neurology article, mild cognitive impairment is another name for the prodromal stage of Alzheimer’s disease (MCI).

The report assesses the market according to therapeutics and diagnostics. Here, the therapeutics segment comprises disease stage, drug type, and generic & branded. Disease stage is further classified into late stage: severe AD, early/middle stage: mild to moderate AD, and prodromal stage.

The noteworthy players in the Alzheimer’s disease therapeutics and diagnostics market include Teva Pharmaceutical Industries Ltd, Merck and Co, Johnson and Johnson, Baxter International Inc, Allergan Plc (acquired by Abbvie), Amarantus Bioscience Holdings Inc, Sun Pharmaceuticals Industries Ltd, Novartis AG, and Eisai Co Ltd.

Johnson and Johnson is an investment holding company with a focus on healthcare items. It is engaged in developing, manufacturing, and marketing surgical equipment, pharmaceuticals, and personal care items. Pharmaceuticals, Medical Devices, and Consumer are the three business segments through which the company operates. Galantamine is approved to treat the symptoms of mild to moderate Alzheimer’s disease, such as memory loss. In the United States, it is sold under the brand names Razadyne and Razadyne ER. The company was founded in 1886 and has a vast business experience. The company has established R&D facilities in several countries, including Brazil.

 

Key deliverables of the report:

·       Market CAGR during the forecasting years 2022-2028

·       Detailed data highlighting key insights, industry components, and market strategies

·       Comprehensive information and estimation of the Alzheimer’s disease therapeutics and diagnostics market revenue growth in Latin America and its influence on the parent market

·       In-depth study of forthcoming trends in consumer behavioral patterns

·       A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model

·       A wide-ranging study of factors that will challenge the Latin America Alzheimer’s disease therapeutics and diagnostics market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.2. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.3. KEY INSIGHTS

2.3.1. USAGE OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE

2.3.2. R&D INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA

2.3.3. DEMAND FOR PERSONALIZED MEDICINES 

2.4. IMPACT OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.5. PORTER’S FIVE FORCES ANALYSIS

2.6. MARKET ATTRACTIVENESS MATRIX

2.7. VENDOR SCORECARD

2.8. INDUSTRY COMPONENTS

2.8.1. RESEARCH & DEVELOPMENT (R & D)

2.8.2. RAW MATERIALS

2.8.3. MANUFACTURING

2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS

2.8.5. END-USER

2.9. KEY IMPACT ANALYSIS

2.9.1. EFFECTIVENESS

2.9.2. PRICE

2.9.3. SAFETY

2.10. KEY MARKET STRATEGIES

2.10.1. ACQUISITIONS

2.10.2. PRODUCT LAUNCHES

2.10.3. CONTRACTS & AGREEMENTS

2.10.4. INVESTMENTS & EXPANSIONS

2.11. MARKET DRIVERS

2.11.1. PREVALENCE OF ALZHEIMER’S DISEASE

2.11.2. RISE IN THE ELDERLY POPULATION

2.12. MARKET CHALLENGES

2.12.1. FAILURE OF LATE-STAGE DRUGS

2.12.2. STRINGENT GOVERNMENT REGULATIONS

2.13. MARKET OPPORTUNITIES

2.13.1. EMERGENCE OF NEW DIAGNOSTIC TECHNOLOGIES

2.13.2. GROWING NUMBER OF PIPELINE DRUGS

3. LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS

3.1. BY DRUG TYPE

3.1.1. MARKETED DRUGS

3.1.2. PIPELINE DRUGS

3.2. BY DISEASE STAGE

3.2.1. LATE STAGE: SEVERE AD

3.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.2.3. PRODROMAL STAGE

3.3. BY GENERIC & BRANDED

3.3.1. BRANDED

3.3.2. GENERIC

4. LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS

4.1. LUMBAR PUNCTURE TEST

4.2. POSITRON EMISSION TOMOGRAPHY

4.3. ELECTROENCEPHALOGRAPHY

4.4. MAGNETIC RESONANCE IMAGING

4.5. COMPUTED TOMOGRAPHY

4.6. BLOOD TEST

4.7. OTHER DIAGNOSTICS

5. LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY OUTLOOK

5.1. BRAZIL

5.2. MEXICO

5.3. REST OF LATIN AMERICA

6. COMPETITIVE LANDSCAPE

6.1. BAXTER INTERNATIONAL INC

6.2. F. HOFFMANN-LA ROCHE AG

6.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)

6.4. NOVARTIS AG

6.5. PFIZER INC

6.6. SIEMENS HEALTHINEERS AG

6.7. AMARANTUS BIOSCIENCE HOLDINGS INC

6.8. EISAI CO LTD

6.9. ELI LILLY & COMPANY

6.10. LUPIN LIMITED

6.11. MERCK AND CO

6.12. BIOGEN INC

6.13. COGNOPTIX INC

6.14. GE HEALTHCARE

6.15. JOHNSON AND JOHNSON

6.16. SUN PHARMACEUTICALS INDUSTRIES LTD

6.17. TEVA PHARMACEUTICAL INDUSTRIES LTD

6.18. ZYDUS CADILA

7. METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)         

TABLE 2: MARKET ATTRACTIVENESS MATRIX      

TABLE 3: VENDOR SCORECARD       

TABLE 4: KEY STRATEGIC DEVELOPMENTS

TABLE 5: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 6: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)       

TABLE 7: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)

TABLE 8: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION) 

TABLE 9: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 10: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)          

List of Figures

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: KEY IMPACT ANALYSIS

FIGURE 3: TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS

FIGURE 4: INDUSTRY COMPONENTS          

FIGURE 5: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021 & 2028 (IN %)

FIGURE 6: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)

FIGURE 7: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 8: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 9: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN %)

FIGURE 10: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028 (IN $ MILLION)

FIGURE 11: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2028 (IN $ MILLION)

FIGURE 12: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $ MILLION)

FIGURE 13: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 & 2028 (IN %)

FIGURE 14: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)

FIGURE 15: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)

FIGURE 16: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021 & 2028 (IN %)

FIGURE 17: LATIN AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN $ MILLION)

FIGURE 18: LATIN AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 19: LATIN AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 20: LATIN AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2028 (IN $ MILLION)

FIGURE 21: LATIN AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 22: LATIN AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)

FIGURE 23: LATIN AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $ MILLION)

FIGURE 24: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)    

FIGURE 25: BRAZIL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 26: MEXICO ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 27: REST OF LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;